New Strategies for Triple-negative Breast Cancer--deciphering the Heterogeneity

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2014 Feb 19

PMID 24536073

Citations 151

Authors

Ingrid A Mayer

Vandana G Abramson

Brian D Lehmann

Jennifer A Pietenpol

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biology. Exploring novel approaches to treatment of these subtypes is critical because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy. To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the standard treatment. We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.

Citing Articles

Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.

Blaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A Cancers (Basel). 2025; 17(2).

PMID: 39858010 PMC: 11764116. DOI: 10.3390/cancers17020228.

Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis.

Dai Y, Ruan T, Yang W, Liu S, Chen J, Fang Y Clin Med Insights Oncol. 2024; 18:11795549241308072.

PMID: 39734512 PMC: 11672372. DOI: 10.1177/11795549241308072.

Loss of WWOX contributes to cisplatin resistance in triple-negative breast cancer cells by modulating miR-182 and miR-214.

Batar B, Serdal E, Erdal B, Ogul H Turk J Med Sci. 2024; 54(5):1127-1134.

PMID: 39473747 PMC: 11518363. DOI: 10.55730/1300-0144.5891.

Effects of polystyrene nano- and microplastics on human breast epithelial cells and human breast cancer cells.

Schnee M, Sieler M, Dornen J, Dittmar T Heliyon. 2024; 10(20):e38686.

PMID: 39449700 PMC: 11497447. DOI: 10.1016/j.heliyon.2024.e38686.

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.

Zhou Z, Si Y, Zhang J, Chen K, George A, Kim S Cancer Res. 2024; 84(22):3848-3863.

PMID: 39186778 PMC: 11565169. DOI: 10.1158/0008-5472.CAN-23-4099.

References

Chen X, Li J, Gray W, Lehmann B, Bauer J, Shyr Y . TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform. 2012; 11:147-56. PMC: 3412597. DOI: 10.4137/CIN.S9983. View

Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P . How basal are triple-negative breast cancers?. Int J Cancer. 2008; 123(1):236-40. DOI: 10.1002/ijc.23518. View

Matros E, Wang Z, Lodeiro G, Miron A, Iglehart J, Richardson A . BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005; 91(2):179-86. DOI: 10.1007/s10549-004-7603-8. View

Taniguchi T, Garcia-Higuera I, Andreassen P, Gregory R, Grompe M, DAndrea A . S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood. 2002; 100(7):2414-20. DOI: 10.1182/blood-2002-01-0278. View

von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P . Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796-804. DOI: 10.1200/JCO.2011.38.8595. View

Turner N, Tutt A, Ashworth A . Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005; 5(4):388-93. DOI: 10.1016/j.coph.2005.03.006. View

Yoshida K, Miki Y . Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004; 95(11):866-71. PMC: 11159131. DOI: 10.1111/j.1349-7006.2004.tb02195.x. View

Gelmon K, Tischkowitz M, MacKay H, Swenerton K, Robidoux A, Tonkin K . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011; 12(9):852-61. DOI: 10.1016/S1470-2045(11)70214-5. View

Wong K, Engelman J, Cantley L . Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2009; 20(1):87-90. PMC: 2822054. DOI: 10.1016/j.gde.2009.11.002. View

10.

Hoeflich K, OBrien C, Boyd Z, Cavet G, Guerrero S, Jung K . In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009; 15(14):4649-64. DOI: 10.1158/1078-0432.CCR-09-0317. View

11.

Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C . Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2008; 115(2):359-63. DOI: 10.1007/s10549-008-0128-9. View

12.

Silver D, Richardson A, Eklund A, Wang Z, Szallasi Z, Li Q . Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010; 28(7):1145-53. PMC: 2834466. DOI: 10.1200/JCO.2009.22.4725. View

13.

Ibrahim Y, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A . PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012; 2(11):1036-47. PMC: 5125254. DOI: 10.1158/2159-8290.CD-11-0348. View

14.

Bhattacharyya A, Ear U, Koller B, Weichselbaum R, Bishop D . The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000; 275(31):23899-903. DOI: 10.1074/jbc.C000276200. View

15.

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

16.

Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J . Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997; 88(2):265-75. DOI: 10.1016/s0092-8674(00)81847-4. View

17.

Juvekar A, Burga L, Hu H, Lunsford E, Ibrahim Y, Balmana J . Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012; 2(11):1048-63. PMC: 3733368. DOI: 10.1158/2159-8290.CD-11-0336. View

18.

Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44. DOI: 10.1016/S0140-6736(10)60892-6. View

19.

Millikan R, Newman B, Tse C, Moorman P, Conway K, Dressler L . Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2007; 109(1):123-39. PMC: 2443103. DOI: 10.1007/s10549-007-9632-6. View

20.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View